Table 4

Summary of findings for the main comparisons: FeNO-based paediatric studies

Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms
Patient or population: children with asthma
Setting: outpatient
Intervention: asthma treatment tailored on FeNO
Comparison: asthma treatment tailored on clinical symptoms
OutcomesAnticipated absolute effects* (95% CI)Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with clinical symptomsRisk with asthma treatment tailored on FeNO
No of participants who had ≥1 exacerbations over the study period
(48.5 weeks)
40 per 10028 per 100
(23 to 33)
OR 0.58
(0.45 to 0.75)
1279
(8 RCTs)
⊕⊕⊕⊝
Moderate1
No of asthma exacerbations per 52 weeks (exacerbation rate)The mean number of asthma exacerbations per 52 weeks (exacerbation rate) was 1.66The mean number of asthma exacerbations per 52 weeks (exacerbation rate) in the intervention group was 0.37 lower (0.8 lower to 0.06 higher)MD −0.37 (−0.8 to 0.06)736
(4 RCTs)
⊕⊝⊝⊝
Very low2
ICS dose at final visit (budesonide equivalent)The mean ICS dose at final visit (budesonide equivalent) was 483 µg/dayThe mean ICS dose at final visit (budesonide equivalent) in the intervention group was 63.95 µg/day higher (51.89 lower to 179.79 higher)317
(3 RCTs)
⊕⊕⊕⊝
Moderate3
  • *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

  • FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; MD, mean difference; RCT, randomised controlled trial.